Roche joins forces with ChemRar on developing new antithrombotic drug for Russia

Swiss pharmaceutical major Roche (ROG: SIX) and Russian TeaReks company, a subsidiary of ChemRar, Roche's long-standing partner, have signed a licensing agreement on the development of an innovative drug for patients at risk of thrombosis, according to the companies.

Under the terms of the agreement, TeaReks will focus on the development of the drug, and its commercialization and distribution in Russia and 12 other countries of the world.

As part of the deal, Roche will provide TeaReks with inhibitors of Xa factor of a new class of drug, that is currently still under investigation. The Swiss company will be also involved in the project through the production of an active pharmaceutical ingredient in its own high-tech base in the USA. At the same time finished dosage form of the drug is expected to produce in Russia.